BACKGROUND: It is unclear whether the higher burden from colorectal cancer among blacks is due to an increased biological susceptibility. OBJECTIVE: To determine whether non-Hispanic blacks (blacks) have a higher risk of adenoma recurrence than non-Hispanic whites (whites) after removal of colorectal adenoma. DESIGN: Secondary analysis of the Polyp Prevention Trial (PPT) data. SETTING: United States. PATIENTS: Patients were 1668 self-identified whites and 153 blacks who completed the 4-year trial. Of these, 688 whites and 55 blacks enrolled in a posttrial, passive Polyp Prevention Trial Continued Follow-up Study (PPT-CFS) and underwent another colonoscopy. MAIN OUTCOME MEASUREMENTS: Recurrence and location of the adenoma and advanced adenoma by race-ethnicity during PPT and cumulative recurrence over a mean follow-up of 8.3 years (range, 4.9-12.4 years) among PPT-CFS enrollees. RESULTS: Blacks had similar risk of recurrence of adenoma (39.2% vs 39.4%; incidence risk ratio [RR] = .98; 95% CI, .80-1.20) and advanced adenoma (8.5% vs 6.4%; RR = 1.18; 95% CI, .68-2.05) as whites at the end of PPT. Recurrence risk did not differ by colon subsite. Among PPT-CFS enrollees, the cumulative recurrence rate over a maximal follow-up period of 12 years was similar for blacks and whites for adenoma (67.3% vs 67.0%; RR = 1.01; 95% CI, .84-1.21) and advanced adenoma (14.5% vs 16.9%; RR = 1.03; 95% CI, .60-1.79). LIMITATION: There were few blacks in the long-term follow-up study. CONCLUSIONS:Adenoma and advanced adenoma recurrence did not differ by race. Our study does not support more frequent surveillance colonoscopies for blacks with a personal history of adenoma as an intervention to reduce colorectal cancer disparity.
RCT Entities:
BACKGROUND: It is unclear whether the higher burden from colorectal cancer among blacks is due to an increased biological susceptibility. OBJECTIVE: To determine whether non-Hispanic blacks (blacks) have a higher risk of adenoma recurrence than non-Hispanic whites (whites) after removal of colorectal adenoma. DESIGN: Secondary analysis of the Polyp Prevention Trial (PPT) data. SETTING: United States. PATIENTS: Patients were 1668 self-identified whites and 153 blacks who completed the 4-year trial. Of these, 688 whites and 55 blacks enrolled in a posttrial, passive Polyp Prevention Trial Continued Follow-up Study (PPT-CFS) and underwent another colonoscopy. MAIN OUTCOME MEASUREMENTS: Recurrence and location of the adenoma and advanced adenoma by race-ethnicity during PPT and cumulative recurrence over a mean follow-up of 8.3 years (range, 4.9-12.4 years) among PPT-CFS enrollees. RESULTS: Blacks had similar risk of recurrence of adenoma (39.2% vs 39.4%; incidence risk ratio [RR] = .98; 95% CI, .80-1.20) and advanced adenoma (8.5% vs 6.4%; RR = 1.18; 95% CI, .68-2.05) as whites at the end of PPT. Recurrence risk did not differ by colon subsite. Among PPT-CFS enrollees, the cumulative recurrence rate over a maximal follow-up period of 12 years was similar for blacks and whites for adenoma (67.3% vs 67.0%; RR = 1.01; 95% CI, .84-1.21) and advanced adenoma (14.5% vs 16.9%; RR = 1.03; 95% CI, .60-1.79). LIMITATION: There were few blacks in the long-term follow-up study. CONCLUSIONS:Adenoma and advanced adenoma recurrence did not differ by race. Our study does not support more frequent surveillance colonoscopies for blacks with a personal history of adenoma as an intervention to reduce colorectal cancer disparity.
Authors: A Schatzkin; E Lanza; D Corle; P Lance; F Iber; B Caan; M Shike; J Weissfeld; R Burt; M R Cooper; J W Kikendall; J Cahill Journal: N Engl J Med Date: 2000-04-20 Impact factor: 91.245
Authors: Chyke A Doubeni; Terry S Field; Diana S M Buist; Eli J Korner; Carol Bigelow; Lois Lamerato; Lisa Herrinton; Virginia P Quinn; Gene Hart; Mark C Hornbrook; Jerry H Gurwitz; Edward H Wagner Journal: Cancer Date: 2007-02-01 Impact factor: 6.860
Authors: A Schatzkin; E Lanza; L S Freedman; J Tangrea; M R Cooper; J R Marshall; P A Murphy; J V Selby; M Shike; R R Schade; R W Burt; J W Kikendall; J Cahill Journal: Cancer Epidemiol Biomarkers Prev Date: 1996-05 Impact factor: 4.254
Authors: E Lanza; A Schatzkin; R Ballard-Barbash; D Corle; C Clifford; E Paskett; D Hayes; E Bote; B Caan; M Shike; J Weissfeld; M Slattery; D Mateski; C Daston; D C Clifford Journal: Cancer Epidemiol Biomarkers Prev Date: 1996-05 Impact factor: 4.254
Authors: Temeika L Fairley; Cheryll J Cardinez; Jim Martin; Linda Alley; Carol Friedman; Brenda Edwards; Patricia Jamison Journal: Cancer Date: 2006-09-01 Impact factor: 6.860
Authors: A David McCollum; Paul J Catalano; Daniel G Haller; Robert J Mayer; John S Macdonald; Al B Benson; Charles S Fuchs Journal: J Natl Cancer Inst Date: 2002-08-07 Impact factor: 13.506
Authors: Joseph C Anderson; John A Baron; Dennis J Ahnen; Elizabeth L Barry; Roberd M Bostick; Carol A Burke; Robert S Bresalier; Timothy R Church; Bernard F Cole; Marcia Cruz-Correa; Adam S Kim; Leila A Mott; Robert S Sandler; Douglas J Robertson Journal: Gastroenterology Date: 2017-02-20 Impact factor: 22.682
Authors: Amy R Marks; Ralph A Pietrofesa; Christopher D Jensen; Alexis Zebrowski; Douglas A Corley; Chyke A Doubeni Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-09-16 Impact factor: 4.254
Authors: Adeyinka O Laiyemo; Chyke Doubeni; Paul F Pinsky; V Paul Doria-Rose; Robert Bresalier; Thomas Hickey; Thomas Riley; Tim R Church; Joel Weissfeld; Robert E Schoen; Pamela M Marcus; Philip C Prorok Journal: J Gen Intern Med Date: 2015-04-03 Impact factor: 5.128
Authors: Kristin Wallace; Carol A Burke; Dennis J Ahnen; Elizabeth L Barry; Robert S Bresalier; Fred Saibil; John A Baron Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-12-09 Impact factor: 4.254
Authors: Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex Journal: Gastroenterology Date: 2020-02-07 Impact factor: 22.682